Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Tougeron

Showing results (51-60 of 235) with videos related to

Pageof 24
Sort By:
Clinical Pharmacokinetics|July 13, 2023
Relationship Between Cetuximab Target-Mediated Pharmacokinetics and Progression-Free Survival in Metastatic Colorectal Cancer PatientsSarah Lobet, Gilles Paintaud, Nicolas Azzopardi, et al.
Helicobacter|March 28, 2018
Th-17 response and antimicrobial peptide expression are uniformly expressed in gastric mucosa of Helicobacter pylori-infected patients independently of their clinical outcomesJulie Cremniter, Charles Bodet, David Tougeron, et al.
Cancer|March 23, 2011
Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO studyAziz Zaanan, Mélanie Gauthier, David Malka, et al.
Future Oncology (London, England)|May 20, 2021
Real-world safety and effectiveness of regorafenib in metastatic colorectal cancer: the French CORRELATE cohortJean-Philippe Metges, Dominique Genet, David Tougeron, et al.
Frontiers in Immunology|January 22, 2026
Tislelizumab efficacy and safety compared to other anti-PD-1s: a network meta-analysis of first-line therapies for unresectable, locally advanced or metastatic esophageal squamous cell carcinomaJaffer A Ajani, Elizabeth Smyth, David Tougeron, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 30, 2017
Clinical outcome of portal vein thrombosis in patients with digestive cancers: A large AGEO multicenter studyHélène Regnault, Sheik Emambux, Thierry Lecomte, et al.
Plos One|April 25, 2013
Regulatory T lymphocytes are associated with less aggressive histologic features in microsatellite-unstable colorectal cancersDavid Tougeron, Pauline Maby, Nicolas Elie, et al.
European Radiology|March 18, 2024
Irreversible electroporation to bring initially unresectable locally advanced pancreatic adenocarcinoma to surgery: the IRECAP phase II studyJean-Pierre Tasu, Guillaume Herpe, Jérôme Damion, et al.
BMC Cancer|March 5, 2025
COVID-19 lockdown-related treatment modifications did not impact the outcome of digestive cancers: the Clin-COVIDICA prospective studyViolaine Randrian, Amale Dhimene, Armelle Pillet, et al.
Cancer|May 10, 2013
Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomasFrank A Sinicrope, Thomas C Smyrk, David Tougeron, et al.
Pageof 24

Showing results (51-60 of 235) with videos related to

Sort By:
Pageof 24
Clinical Pharmacokinetics|July 13, 2023
Relationship Between Cetuximab Target-Mediated Pharmacokinetics and Progression-Free Survival in Metastatic Colorectal Cancer PatientsSarah Lobet, Gilles Paintaud, Nicolas Azzopardi, et al.
Helicobacter|March 28, 2018
Th-17 response and antimicrobial peptide expression are uniformly expressed in gastric mucosa of Helicobacter pylori-infected patients independently of their clinical outcomesJulie Cremniter, Charles Bodet, David Tougeron, et al.
Cancer|March 23, 2011
Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO studyAziz Zaanan, Mélanie Gauthier, David Malka, et al.
Future Oncology (London, England)|May 20, 2021
Real-world safety and effectiveness of regorafenib in metastatic colorectal cancer: the French CORRELATE cohortJean-Philippe Metges, Dominique Genet, David Tougeron, et al.
Frontiers in Immunology|January 22, 2026
Tislelizumab efficacy and safety compared to other anti-PD-1s: a network meta-analysis of first-line therapies for unresectable, locally advanced or metastatic esophageal squamous cell carcinomaJaffer A Ajani, Elizabeth Smyth, David Tougeron, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 30, 2017
Clinical outcome of portal vein thrombosis in patients with digestive cancers: A large AGEO multicenter studyHélène Regnault, Sheik Emambux, Thierry Lecomte, et al.
Plos One|April 25, 2013
Regulatory T lymphocytes are associated with less aggressive histologic features in microsatellite-unstable colorectal cancersDavid Tougeron, Pauline Maby, Nicolas Elie, et al.
European Radiology|March 18, 2024
Irreversible electroporation to bring initially unresectable locally advanced pancreatic adenocarcinoma to surgery: the IRECAP phase II studyJean-Pierre Tasu, Guillaume Herpe, Jérôme Damion, et al.
BMC Cancer|March 5, 2025
COVID-19 lockdown-related treatment modifications did not impact the outcome of digestive cancers: the Clin-COVIDICA prospective studyViolaine Randrian, Amale Dhimene, Armelle Pillet, et al.
Cancer|May 10, 2013
Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomasFrank A Sinicrope, Thomas C Smyrk, David Tougeron, et al.
Pageof 24